Case Summary: INDIAN MEDICAL ASSOCIATION & ANR. V. UNION OF INDIA & ORS., 2024

CASE DETAILS

INTRODUCTON

The Supreme Court examined the increasing problem of false and deceptive advertising practices which particularly impact consumer rights in the health and food industries. The Court studied how manufacturers and advertisers and endorsers and service providers together promoted products through false and unverified claims because public figures and influencers must follow the 2022 Guidelines about misleading advertisements. The Court observed that existing legal frameworks, including the Consumer Protection Act ,1986[1] and regulatory guidelines failed to achieve proper enforcement, which resulted in severe deficiencies for handling customer complaints and for regulatory supervision from organizations like FSSAI. The Indian Medical Association presented their case to the Court after receiving numerous public complaints about misleading endorsements. The Court established a self-declaration mechanism for advertisements and required authorities to provide affidavits about their activities since 2018 while treating these directives as compulsory regulations through Article 141[2] which enhanced consumer protection and responsibility[3].

FACTS

The case arose from a writ petition filed under Article 32[4] which the Indian Medical Association filed against the Union of India. The healthcare and pharmaceutical and food sectors face an increasing problem of deceptive advertisements which now occurs at significant levels.The manufacturers and advertisers and endorsers created false statements which they had not verified to the public, which led to health hazards for consumers. The current Consumer Protection Act establishes legal systems but law enforcement remains ineffective because authorities perform basic monitoring and they investigate only a few customer complaints. The Ministry of AYUSH issued a communication on 29 August 2023, which ordered the suspension of Rule 170 of the Drugs and Cosmetics Rules, 1945[5]. Despite earlier court directions, certain parties continued to publish misleading advertisements and later issued public apologies.

ISSUES

The Supreme Court observed the following issues:

1. Whether the publication of misleading advertisements in the healthcare, pharmaceutical and food sectors infringes consumer rights and also the right to health, an aspect of Article 21[6]?
2. Whether manufacturers, Advertisers & endorsers (including celebrities and influencers) can be held responsible for deceptive advertisements?
3. Are the existing laws and regulatory framework are adequate and effectively implemented to curb misleading advertisements?
4. Whether the Ministry of AYUSH’s communication, dated 29 August, 2023, directing non-enforcement of Rule 170 has the force of law?
5. Can the Supreme Court issue directions under Article 32 to establish a robust regulatory mechanism to prevent misleading advertisements?

 ARGUMENTS ADVANCED

PETITIONER

• The​‍​‌‍​‍‌​‍​‌‍​‍‌ Indian Medical Association (IMA) asserted that the soaring number of misleading ads in the health, pharma, and food industries that are not regulated is a serious threat to public health, and it negatively affects consumers.
• It was claimed that the current trend of using popular celebrities and influencers in such ads that deceive people through false, exaggerated, and unproven claims, is a way advertisers exploit consumers’ ignorance and infringe consumer rights.
• The petitioners noted that misleading ads in the health industry, besides causing other serious consequences, such as patients postponing their treatment or using the wrong/unhealthy products, also attack people’s right to health, which is their constitutional right guaranteed under Article 21 of the Constitution.
• The petitioners submitted that there should be joint and several liability of the manufacturers, advertisers, and endorsers, since they are all responsible for the consumer’s decision-making and the promotion of the products.
• The petitioners maintained that despite the existence of laws such as the Consumer Protection Act and other relevant guidelines, there is still a lack of enforcement and a failure of the regulatory system, as the authorities usually ignore or do not adequately handle the complaints.
• A very strong argument was also directed against the communication of the Ministry of AYUSH dated 29 August 2023, which instructed the enforcement authorities not to implement Rule 170 of the Drugs and Cosmetics Rules, 1945. The petitioners pointed out that this essentially nullifies the statutory protections and dilutes the regulatory framework.
• The petitioners urged the Court to exercise its powers under Article 32, issue non-negotiable, binding orders and establish an efficient advertisement regulatory mechanism to hold advertisers accountable while protecting consumers from unfair, deceptive practices. ​‍​‌‍​‍‌​‍​‌‍​‍‌

RESPONDENT

• The Union of India together with its relevant Ministries, maintained that existing legal regulations already control misleading advertisements through their current execution of the Consumer Protection Act and the Drugs and Cosmetics Act and their established advertising guidelines.
• The authorities established regulatory systems which include the Central Consumer Protection Authority (CCPA) that possesses authority to enforce actions against deceptive and false advertising practices.
• The respondents maintained that various government departments and regulatory agencies including the Ministry of Health and AYUSH and the Ministry of Information and Broadcasting operate to track and resolve false advertising practices. The enforcement process requires organizations to handle complaints through established procedures but they need to work together with multiple organizations to reach their goals.
• The respondents declared that the Ministry of AYUSH sent a communication on 29 August, 2023 which used ASUDTAB recommendations as its source. The communication represented an administrative procedure because the matter remained under consideration and had not achieved legislative confirmation.
• The respondents demonstrated that advertising standards compliance is maintained through self-regulatory systems which include both industry bodies and broadcaster guidelines. The excessive regulation of advertisements needs evaluation because it may adversely affect commercial speech according to the need for balanced advertisement regulation.

JUDGEMENT AND RATIO DECENDI

• The Supreme Court issued its landmark ruling to establish procedures for dealing with deceptive advertisements that particularly affect the health and food advertising industries.
• The Court reached its decision about the ads after the Indian Medical Association submitted their petition because the ads violated consumer rights while they also violated the Article 21 constitutional right to health protection.
• It was observed by the Court that the manufacturers, the promoters, the advertising agencies, and the endorsers, including the celebrities and the social media influencers, should be held equally responsible for misleading advertisements.
• The​‍​‌‍​‍‌​‍​‌‍​‍‌ Court emphasized that even the 2022 guidelines on misleading advertisements and the statutory framework and guidelines that are in place should be thoroughly implemented; merely having laws on the books is not sufficient if people are not actually enforcing them.
• Moreover, it noted that administrative directions, such as the Ministry of AYUSH’s letter dated 29 August 2023 requesting the non-enforcement of Rule 170 of the Drugs and Cosmetics Rules, cannot override the binding statutory ​‍​‌‍​‍‌​‍​‌‍​‍‌provisions.
• To reinforce the system of checks, the Court passed several binding orders under Article 32, including the establishment of a self-declaration system whereby all ads get a go-ahead before going to the press or on air.
• It also ordered the formation of effective systems for lodging complaints and regular submission of affidavits reporting the steps taken against misleading ads. The orders described in Article 141 of the document establish binding legal obligations that require all citizens of India to follow.
• Ratio Decedendi: The main reason for the ruling exists because false advertising violates consumer rights and health rights in critical sectors which include healthcare. The establishment of strict regulations requires not only the parties involved to face accountability but also the creation of compliance systems which must operate effectively and meet legal enforcement standards.

CRITICAL ANALYSIS

• The case establishes new legal protection, particularly in the sensitive health and food sectors. The Supreme Court declares that false claims damage basic human rights which connect to existence and human dignity because they extend beyond commercial matters.
• Misleading advertisements, though commercial in nature, directly affect fundamental rights. As a result of this judgment, answerability expands, addressing what earlier remained overlooked.
• Now comes a shift: self-declarations must be filed by advertisers, placing responsibility firmly with them, though compliance is expected ahead of mandates.
• The judgment strengthens regulatory oversight and highlights institutional weaknesses. Roles within regulatory entities grow more defined only when such flaws come to light.
• Still, some issues persist. Online tracking of adherence becomes challenging because it requires complete dependence on users to report their activities. The decision, through its major responsibilities for monitoring bodies assigns important work to these organizations while it fails to provide complete procedures for enforcing rules and handling compliance violations.
• The ruling provides additional legal protection for buyers because it establishes essential monitoring systems that prove necessary for sustainable change to continue. What follows depends less on courts than steady enforcement woven into daily practice.

CONCLUSION

Despite its quiet arrival, the judgment in Indian Medical Association & Anr. v. Union of India & Ors. reshaped how misleading ads, especially those tied to health and food are challenged legally. Responsibility now extends across every involved entity, following Supreme Court guidance rooted in safeguarding life under Article 21. Clarity in rules may encourage openness in practice; still, actual results hinge upon consistent oversight during execution. Long-term success rests less on wording, more on how diligently systems track adherence over time.

REFERENCES

[1] Consumer Protection Act, No. 68 of 1986, India Code (1986)

[2] INDIA CONST. art. 141.

[3] Indian Medical Association & Anr. v. Union of India & Ors., LawFoyer (Nov. 26, 2024), https://lawfoyer.in/indian-medical-association-anr-vs-union-of-india-ors/

[4] INDIA CONST. art. 32

[5] Drugs & Cosmetics Rules, 1945, r. 170 (India).

[6] INDIA CONST. art. 21